By Dean Seal
Curis Inc. said Thursday the U.S. Food and Drug Administration has lifted the partial clinical hold on its TakeAim Lymphoma study, a Phase 1/2 trial of emavusertib in patients with B-cell malignancies.
The cancer-focused biotechnology company announced the hold back in April, saying at the time that it was unexpected. The notification came from the FDA Division of Hematologic Malignancies 2, which regulates clinical studies in lymphoma.
The FDA lifted the hold after reviewing a comprehensive data package that Curis submitted, according to the company.
Chief Executive James Dentzer said the company is working to resume enrollment of new patients in the third quarter.
Shares soared 29.5% to $1.36 in premarket trading.
Write to Dean Seal at firstname.lastname@example.org
(END) Dow Jones Newswires